Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy

A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus chemotherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fatigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biops...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Tomoka, Ninomiya, Kiichiro, Nakashima, Mitsutaka, Akagi, Satoshi, Kuribayashi, Tadahiro, Higo, Hisao, Hotta, Katsuyuki, Maeda, Yoshinobu, Ito, Hiroshi, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208784/
https://www.ncbi.nlm.nih.gov/pubmed/36130891
http://dx.doi.org/10.2169/internalmedicine.0505-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208784/
https://www.ncbi.nlm.nih.gov/pubmed/36130891
http://dx.doi.org/10.2169/internalmedicine.0505-22

Ejemplares similares